Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.

ABSTRACT:

Objectives

Interleukin-6 (IL-6) is implicated in rheumatoid arthritis (RA) pathophysiology. Unlike IL-6 receptor inhibitors, sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine. The phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group SIRROUND-D study (ClinicalTrials.gov identifier NCT01604343) evaluated the efficacy and safety of sirukumab in patients with active RA refractory to disease-modifying antirheumatic drugs.

Methods

Patients were randomised 1:1:1 to treatment with sirukumab 100 mg every 2 weeks, 50 mg every 4 weeks or placebo every 2 weeks subcutaneously. Results through week 52 are reported.

Results

Of 1670 randomised patients, significantly more patients achieved American College of Rheumato

SUBMITTER: Takeuchi T 

PROVIDER: S-EPMC5705845 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature